Well, that was fast. It took Gov. Jim Justice all of one day after winning a seat in the U.S. Senate to play an exclusive game of political nepotism, appointing ...

Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Mylan CEO Heather Bresch said: "I couldn't be prouder of this approval for Fulphila, the first alternative option for pegfilgrastim approved in the US, as it represents an important milestone for ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

In an interview with the Financial Times, Siddharth Mittal, chief executive officer, Biocon Limited ... We may not be the ...

If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero, and Mylan ... chairman and chief executive officer at Gilead ...

The Nasal Drug Delivery Technology Market is driven by the rising demand for non-invasive administration methods that enhance patient compliance and bioavailability. Innovations such as advanced ...

Viatris is poised for appreciation with new product launches and a stronger balance sheet. Read why VTRS stock is a buy due ...

Clad in his ubiquitous leather jacket, Chief Executive Officer Jensen Huang strode onto the stage in front of a large screen displaying a row of humanoid robots straight out of a Philip K.